コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 de related to advances in both radiation and medical oncology.
2 Drug resistance is a major impediment in medical oncology.
3 ited for supporting therapeutic decisions in medical oncology.
4 hallenges posed by this emerging paradigm in medical oncology.
5 ave had a substantial impact on the field of medical oncology.
6 oming integrated into the practice of modern medical oncology.
7 anding possible adverse drug interactions in medical oncology.
8 os were mailed to ASCO members who practiced medical oncology.
9 d, value-oriented approach in hematology and medical oncology.
10 n oncologists and hematologists who practice medical oncology.
11 worked in radiation oncology, 344 (34.3%) in medical oncology, 186 (18.4%) in surgical oncology, and
12 linical Oncology and the European Society of Medical Oncology (2004-09) for relevant clinical trials.
14 g strong communication between pediatric and medical oncology (48%), having a supportive research inf
15 LLMs from other fields may not generalize to medical oncology, a high-stakes clinical setting requiri
16 collaboration with the European Society for Medical Oncology, a novel international staging system (
18 nazi Jewish women with breast cancer seen at medical oncology and genetic counseling clinics in New Y
19 in which we randomly assigned 15 clusters of medical oncology and haematology clinics in the USA shar
21 unication issues (27%) between pediatric and medical oncology and perceived limited trial availabilit
22 ssociation between network vulnerability for medical oncology and percent of cohort patients receivin
23 how ChatGPT can be of value to medicine and medical oncology and the potential pitfalls that may be
24 r head and neck surgery, radiation oncology, medical oncology, and clinical oncology with vast experi
27 iplinary group (surgery, radiation oncology, medical oncology, and pathology) and were offered three
29 om radiology, thoracic surgery, pulmonology, medical oncology, and radiation oncology reviewed all no
30 the introduction of innovative therapies in medical oncology, and they provide the highest level of
31 erican Board of Internal Medicine recognized medical oncology as a subspecialty, creating tensions be
32 e, we propose the ESMO (European Society for Medical Oncology) Basic Requirements for AI-based Biomar
33 ry breast cancer who had a consultation with medical oncology between October 1, 2017, through Septem
34 n breast cancer clinical trials representing medical oncology, biostatistics, and correlative science
35 elligence-based solutions in the practice of medical oncology by discussing some of the related pragm
36 imaging has facilitated drug development in medical oncology by providing quantifiable and objective
37 ns of improving access and reducing cost for medical oncology care; however, use by specialists prior
38 Risk-Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guideline published i
39 ncreasing coordination between pediatric and medical oncology clinical trials offices and providers h
40 d between 2014 and 2020 were identified from medical oncology clinics and (18)F-FDG PET/CT records.
41 academic dermatology, medical genetics, and medical oncology clinics between July 2014 and July 2022
42 encounters at 9 tertiary or community-based medical oncology clinics in a large academic health syst
43 linical trial conducted at 91 US urology and medical oncology clinics that enrolled 478 men aged 50 t
48 eferred to the authors' European Society for Medical Oncology-designated cancer center from January t
49 Endocrine tumors are often overlooked in medical oncology discussions, as many of them are effect
50 cological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Path
52 t recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for
53 survey conducted by the European Society for Medical Oncology (ESMO) Clinical Research Observatory (E
54 In December, 2013, the European Society for Medical Oncology (ESMO) convened a consensus meeting to
55 Oncology (ASCO) and the European Society for Medical Oncology (ESMO) developed frameworks to evaluate
57 f Neuro-Oncology (EANO)-European Society for Medical Oncology (ESMO) diagnostic criteria, type I (cer
58 on ASCO Connection, the European Society of Medical Oncology (ESMO) Examination Trial questions, and
59 n 2013 on behalf of the European Society for Medical Oncology (ESMO) Guidelines Working Group in Anna
61 Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have developed frameworks that q
64 ween 2022 and 2023, the European Society for Medical Oncology (ESMO) held a virtual consensus-buildin
65 Value Framework and the European Society for Medical Oncology (ESMO) Magnitude of Clinical Benefit Sc
66 Oncology (ASCO) and the European Society of Medical Oncology (ESMO) meetings held between 2004 and 2
68 icine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group
69 pert subgroup under the European Society for Medical Oncology (ESMO) Precision Medicine Working Group
71 epresentatives from the European Society for Medical Oncology (ESMO) Precision Oncology Working Group
72 was assessed using the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability
73 was assessed using the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability
78 ese therapies using the European Society for Medical Oncology (ESMO)-Magnitude of Clinical Benefit Sc
80 ectional study of the performance of LLMs on medical oncology examination questions, the best LLM ans
81 ical parameters of TCR mechanobiology to the medical oncology field, broadening treatment success wit
84 Myeloma Network and the European Society for Medical Oncology guidelines have recommended WBLDCT as t
87 from October 30, 2019, to March 5, 2020, of medical oncology health professionals at the Thomas Jeff
90 s used, resulting in the participation of 29 medical oncology health professionals, including 20 phys
91 partment of dermatology and 2 departments of medical oncology in France between January 2008 and Dece
92 ncology (ASCO) developed its own test -- the Medical Oncology In-Training Examination (MedOnc ITE) --
94 by both the ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special virtual gui
95 nning 388 outpatient centers and clinics for medical oncology located in 44 states across the US.
96 ersion 2.0 (ASCO-VF) and European Society of Medical Oncology Magnitude of Clinical Benefit Scale ver
97 nefit (score of 1 on the European Society of Medical Oncology Magnitude of Clinical Benefit Scale).
98 troduced frameworks-the European Society for Medical Oncology Magnitude of Clinical Benefit Scale, th
99 ogy Value Framework and European Society for Medical Oncology Magnitude of Clinical Benefit Scale.
101 efit evaluated with the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ES
102 t was assessed using the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale (ES
103 l [PFS]), including the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ES
105 s head and neck surgery, radiation oncology, medical oncology, medical imaging, clinical pathology an
106 f Clinical Oncology and European Society for Medical Oncology Meeting Libraries, and Web of Science w
107 of Clinical Oncology and European Society of Medical Oncology meeting proceedings were systematically
108 f Clinical Oncology and European Society for Medical Oncology meetings' libraries, Kaplan-Meier curve
109 uestions, and an original set of board-style medical oncology multiple-choice questions were presente
110 f experts representing hematologic oncology, medical oncology, neuro-oncology, neurology, radiation o
112 2DEC005), Tanoto Foundation Professorship in Medical Oncology, New Century Foundation Limited, Ling F
113 rvative surgery and radiation therapy and 20 medical oncology nurses were assessed for five health st
114 Group of Radiation Oncology/Working Group of Medical Oncology of the Germany Cancer Society] trial, p
116 dult (aged >=18 years) patients who received medical oncology or haematology care in a US multi-state
118 es (paediatric oncology, paediatric surgery, medical oncology, pathology, psycho-oncology, gynaecolog
119 y convened an Update Committee of experts in medical oncology, pathology, radiation oncology, surgica
120 f palliative care specialists in the care of medical oncology patients has been repeatedly observed t
123 ogy member physicians in 2006 as a voluntary medical oncology practice-based quality measurement and
124 ords of 8662 patients treated with HEC at 38 medical oncology practices at 71 sites across the state.
128 s ASCO convened a multidisciplinary panel of medical oncology, psychiatry, nursing, hospice and palli
129 primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing was fo
130 ety of Clinical Oncology convened a panel of medical oncology, radiation oncology, guideline implemen
131 Clinical Oncology (ASCO) convened a panel of medical oncology, radiation oncology, guideline implemen
132 independent group of experts across urology, medical oncology, radiation oncology, radiology, patholo
133 nts were all 285 clinicians in the fields of medical oncology, radiation oncology, surgical oncology,
134 ned an expert panel of integrative oncology, medical oncology, radiation oncology, surgical oncology,
135 ned an expert panel of integrative oncology, medical oncology, radiation oncology, surgical oncology,
136 linical Oncology convened an Expert Panel of medical oncology, radiation oncology, surgical oncology,
138 linical Oncology convened an Expert Panel of medical oncology, radiation oncology, surgical oncology,
139 ch identified all English-language phase III medical oncology randomized clinical trials (RCTs) publi
140 had significantly fewer outpatient visits in medical oncology (rate ratio, 0.86; 95% CI, 0.86-0.89; P
141 nditions was associated with reduced odds of medical oncology referral (odds ratio, 0.65; 95% CI, 0.5
142 iagnosis was associated with reduced odds of medical oncology referral and surveillance colonoscopy.
143 noembryonic antigen, clear surgical margins, medical oncology referral for stages II and III, fluorou
145 ead and neck cancer surgical, radiation, and medical oncology, representing 35 international professi
146 ake-up according to the European Society for Medical Oncology Scale for Clinical Actionability of mol
147 tios, lung transplantation services, complex medical oncology services, bariatric surgery services, a
150 cer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advoc
151 linical Oncology convened an Expert Panel of medical oncology, surgery, radiation oncology, radiology
152 adjuvant Melanoma Consortium with experts in medical oncology, surgical oncology, pathology, radiatio
162 cell lymphoma treated at the Wessex Regional Medical Oncology Unit in Southampton between 1979 and 19
164 se pharmacies was measured in 5 specialties: medical oncology, urology, infectious disease, gastroent